Matching articles for "vericiguat"
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • June 14, 2021; (Issue 1626)
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension and
chronic thromboembolic pulmonary hypertension,
was the first.
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
...
View the Comparison Table: Some Drugs for HFrEF